Scholars Central

Case reportPublished 31 Dec 2022

Immunotherapy and General Medical Aid in Metastatic/Recurrent Mucous Membrane and Cervical Cancers

Authors: Igor Tsaur

Department of Urology and Pediatric Urology, University Medicine Mainz, Mainz, Germany

Cervical Cancer: Open Access

Volume 7 · Issue 6 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Despite advances within the treatment of medical specialty malignancies, each repeated mucosa and cervical cancers once not amenable to localised medical care (surgery or radiotherapy), stay incurable with restricted prognosis and effective treatment choices. Therapy remains the quality of take care of girls with pathological process mucosa or cervical cancers. The addition of bevacizumab to first-line therapy for pathological process cervical cancer patients represents a major breakthrough in up survival. Additional recently, therapy methods targeting the PD-1/-L1 pathway have shown clinical activity in each mucosa and cervical cancers. The accrued understanding of the biology of those cancers is shaping target-specific treatments. Here we have a tendency to summarise current treatment choices and results from clinical trials of therapy and different targeted therapies that have already modified, or have the potential to vary, clinical observe in metastatic/recurrent mucosa and cervical cancer

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCervical Cancer: Open Access
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Igor Tsaur”